Akumin (NASDAQ:AKU – Get Rating) is one of 46 publicly-traded companies in the "Medical laboratories" industry, but how does it weigh in compared to its competitors? We will compare Akumin to related companies based on the strength of its dividends, profitability, analyst recommendations, risk, earnings, institutional ownership and valuation.
Analyst Recommendations
This is a breakdown of recent ratings for Akumin and its competitors, as provided by MarketBeat.com.
Get Akumin alerts:| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Akumin | 2 | 0 | 0 | 0 | 1.00 |
| Akumin Competitors | 136 | 719 | 1614 | 30 | 2.62 |
Akumin presently has a consensus price target of $0.63, indicating a potential downside of 63.45%. As a group, "Medical laboratories" companies have a potential upside of 100.90%. Given Akumin's competitors stronger consensus rating and higher probable upside, analysts plainly believe Akumin has less favorable growth aspects than its competitors.
Valuation and Earnings
This table compares Akumin and its competitors revenue, earnings per share (EPS) and valuation.| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Akumin | $421.08 million | -$43.29 million | -1.60 |
| Akumin Competitors | $1.04 billion | $57.33 million | -0.06 |
Akumin's competitors have higher revenue and earnings than Akumin. Akumin is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Risk & Volatility
Akumin has a beta of 0.04, indicating that its share price is 96% less volatile than the S&P 500. Comparatively, Akumin's competitors have a beta of -1.65, indicating that their average share price is 265% less volatile than the S&P 500.
Insider & Institutional Ownership
25.1% of Akumin shares are held by institutional investors. Comparatively, 53.5% of shares of all "Medical laboratories" companies are held by institutional investors. 17.0% of shares of all "Medical laboratories" companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Akumin and its competitors' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Akumin | -14.16% | -29.00% | -3.87% |
| Akumin Competitors | -1,501.07% | -52.65% | -22.32% |
Summary
Akumin competitors beat Akumin on 9 of the 13 factors compared.
About Akumin
(Get Rating)
Akumin Inc. provides outpatient diagnostic imaging services in the United States. It operates in two segments, Radiology and Oncology. The company offers various medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, digital radiography, fluoroscopy, and other diagnostic or interventional radiology procedures through a network of approximately 200 owned and/or operated imaging locations. It provides outpatient radiology, and oncology services and solutions to approximately 1,000 hospitals and health systems across 46 states. Akumin Inc. was founded in 2015 and is headquartered in Plantation, Florida.
Receive News & Ratings for Akumin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akumin and related companies with MarketBeat.com's FREE daily email newsletter.